Technology | October 29, 2010

New Radiation Therapy Solutions Launched at ASTRO

October 29. 2010 – The company D3 Radiation Planning has changed its name to D3 Radiation Oncology Solutions. The company chose its new name to reflect the recent expansion in the number of new solutions that D3 offers to accelerate excellence in radiation oncology.

"The future of radiation oncology belongs to those practices that recognize and address changes and challenges in the field today," said Kathy Lokay, president and CEO, D3 Radiation Oncology Solutions. "Continuing to build on our affiliation with UPMC and UPMC Cancer Centers, D3 has new solutions to help practices achieve and sustain excellence – in quality, safety, efficiency, and outcomes."

D3's new suite of solutions, which will be launched at the upcoming ASTRO Annual Meeting in San Diego, includes:

• D3 Radiation Oncology Pathways: The pathway solution for radiation oncology is developed and maintained by a distinguished group of academic and community radiation oncologists. D3 Radiation Oncology Pathways provide treatment recommendations for each unique patient presentation in a Web-based interactive decision support tool. In an era of increased payer scrutiny over the appropriateness of utilization and costs of cancer care, D3 Radiation Oncology Pathways help practices prove their quality and avoid external administrative oversight.

• D3 Quality Assurance and Peer Review Programs: These solutions support practices to ensure quality and patient safety, differentiate themselves in their market, and prepare to achieve American College of Radiology (ACR) or American College of Radiation Oncology (ACRO) accreditation.

• Flexible Options for Treatment Planning: D3 now offers practices with multiple locations and high patient volume assistance in establishing their own centralized treatment planning centers of excellence. D3 also continues to offer On-Demand Dosimetry to centers experiencing short- or long-term dosimetry staff vacancies. D3's expertise in treatment planning is unsurpassed. Since 2001, D3 has developed more than 20,000 treatment plans.

• Clinical Training: D3's experienced, ABR board certified and clinically active medical physicists and dosimetrists work in collaboration with practices to accelerate and optimize the application of advanced technologies through hands-on operations and clinical training coupled with extensive post-training validation and peer review.

• Commissioning: Whether fully outsourced or facilitated, D3's commissioning solutions are performed in a consultative manner with a rigorous methodology from acceptance testing and data collection to modeling and validation. And D3 now has experience commissioning Varian TrueBeam.

"Our clinical staff has an average of 20 years of radiation oncology experience, and since 2001 we have supported more than 250 practices in the U.S. and internationally," said Greg Ross, chief operating officer, D3 Radiation Oncology Solutions. "With the D3 suite of solutions, we are applying our expertise and experience to help practices be successful as they face today's intensifying demands for quality, safety and efficiency."

D3 Radiation Oncology Solutions is exhibiting at the American Society for Radiation Oncology (ASTRO) Annual Meeting at the San Diego Convention Center, Oct. 31 – Nov. 3, 2010. D3 will be at booth 121.

For more information: www.d3rad.com

Related Content

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res